Lucid Diagnostics (NASDAQ:LUCD) Upgraded to “Hold” at Wall Street Zen

Lucid Diagnostics (NASDAQ:LUCD) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other research analysts also recently commented on the company. Ascendiant Capital Markets upped their price objective on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $3.94.

Lucid Diagnostics Stock Down 2.0%

NASDAQ:LUCD opened at $1.44 on Friday. The company has a market cap of $198.26 million, a PE ratio of -1.38 and a beta of 1.22. The business’s 50 day moving average is $1.22 and its two-hundred day moving average is $1.15. Lucid Diagnostics has a 52 week low of $0.95 and a 52 week high of $1.80.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Quadrature Capital Ltd purchased a new stake in Lucid Diagnostics during the second quarter valued at about $29,000. Centiva Capital LP purchased a new position in shares of Lucid Diagnostics in the third quarter worth approximately $25,000. Sprott Inc. acquired a new stake in shares of Lucid Diagnostics during the third quarter valued at approximately $25,000. Cubist Systematic Strategies LLC acquired a new position in Lucid Diagnostics in the 1st quarter worth approximately $39,000. Finally, SG Americas Securities LLC acquired a new stake in Lucid Diagnostics during the 3rd quarter valued at $26,000. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.